Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8ERA

RMC-5552 in complex with mTORC1 and FKBP12

8ERA の概要
エントリーDOI10.2210/pdb8era/pdb
EMDBエントリー28551
分子名称Serine/threonine-protein kinase mTOR, Peptidyl-prolyl cis-trans isomerase FKBP1A, Target of rapamycin complex subunit LST8, ... (6 entities in total)
機能のキーワードantitumor, mtorc1, complex (isomerase-kinase) complex, complex (isomerase/kinase)
由来する生物種Homo sapiens (human)
詳細
タンパク質・核酸の鎖数4
化学式量合計487692.36
構造登録者
Tomlinson, A.C.A.,Yano, J.K. (登録日: 2022-10-11, 公開日: 2022-12-28, 最終更新日: 2024-06-19)
主引用文献Burnett, G.L.,Yang, Y.C.,Aggen, J.B.,Pitzen, J.,Gliedt, M.K.,Semko, C.M.,Marquez, A.,Evans, J.W.,Wang, G.,Won, W.S.,Tomlinson, A.C.A.,Kiss, G.,Tzitzilonis, C.,Thottumkara, A.P.,Cregg, J.,Mellem, K.T.,Choi, J.S.,Lee, J.C.,Zhao, Y.,Lee, B.J.,Meyerowitz, J.G.,Knox, J.E.,Jiang, J.,Wang, Z.,Wildes, D.,Wang, Z.,Singh, M.,Smith, J.A.M.,Gill, A.L.
Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors.
J.Med.Chem., 66:149-169, 2023
Cited by
PubMed Abstract: Hyperactivation of mTOR kinase by mutations in the PI3K/mTOR pathway or by crosstalk with other mutant cancer drivers, such as RAS, is a feature of many tumors. Multiple allosteric inhibitors of mTORC1 and orthosteric dual inhibitors of mTORC1 and mTORC2 have been developed as anticancer drugs, but their clinical utility has been limited. To address these limitations, we have developed a novel class of "bi-steric inhibitors" that interact with both the orthosteric and the allosteric binding sites in order to deepen the inhibition of mTORC1 while also preserving selectivity for mTORC1 over mTORC2. In this report, we describe the discovery and preclinical profile of the development candidate RMC-5552 and the in vivo preclinical tool compound RMC-6272. We also present evidence that selective inhibition of mTORC1 in combination with covalent inhibition of KRAS shows increased antitumor activity in a preclinical model of mutant NSCLC that exhibits resistance to KRAS inhibitor monotherapy.
PubMed: 36533617
DOI: 10.1021/acs.jmedchem.2c01658
主引用文献が同じPDBエントリー
実験手法
ELECTRON MICROSCOPY (2.86 Å)
構造検証レポート
Validation report summary of 8era
検証レポート(詳細版)ダウンロードをダウンロード

246905

件を2025-12-31に公開中

PDB statisticsPDBj update infoContact PDBjnumon